Center for Reproductive Medicine, Department of Gynecology & Obsterics, Tang Du Hospital, the Air Force Military Medical University, Xi'an, Shaan xi, People's Republic of China.
J Assist Reprod Genet. 2022 Aug;39(8):1927-1936. doi: 10.1007/s10815-022-02557-2. Epub 2022 Jun 29.
To compare aneuploidy rates in early aborted tissues or blastocysts between in vitro fertilization (IVF) cycles after the gonadotropin-releasing hormone (GnRH) antagonist (GnRH-ant) protocol or the GnRH agonist (GnRH-a) long protocol.
This was a retrospective cohort study from a university-affiliated fertility center. In total, 550 early miscarriage patients who conceived through IVF/intracytoplasmic sperm injection (ICSI) after receiving the GnRH-ant or GnRH-a long protocol were analyzed to compare aneuploidy rates in early aborted tissues. To compare aneuploidy rates in blastocysts, 404 preimplantation genetic testing for aneuploidy (PGT-A) cycles with the GnRH-ant protocol or GnRH-a long protocol were also analyzed.
For early miscarriage patients who conceived through IVF/ICSI, compared to the GnRH-a long protocol group, the GnRH-ant protocol group had a significantly higher rate of aneuploidy in early aborted tissues (48.51% vs. 64.19%). Regarding PGT-A cycles, the rate of blastocyst aneuploidy was significantly higher in the GnRH-ant protocol group than the GnRH-a long protocol group (39.69% vs. 52.27%). After stratification and multiple linear regression, the GnRH-ant regimen remained significantly associated with an increased risk of aneuploidy in early aborted tissues and blastocysts [OR (95% CI) 1.81 (1.21, 2.71), OR (95% CI) 1.65 (1.13, 2.42)]. Furthermore, the blastocyst aneuploidy rate in the GnRH-ant protocol group was significantly higher but only in young and normal ovarian responders [OR (95% CI) 5.07 (1.99, 12.92)].
Compared to the GnRH-a long protocol, the GnRH-ant protocol is associated with a higher aneuploidy rate in early aborted tissues and blastocysts. These results should be confirmed in a multicenter, randomized controlled trial.
比较 GnRH 拮抗剂(GnRH-ant)方案和 GnRH 激动剂(GnRH-a)长方案的体外受精(IVF)周期中早期流产组织或囊胚的非整倍体率。
这是一项来自大学附属生育中心的回顾性队列研究。共分析了 550 例接受 GnRH-ant 或 GnRH-a 长方案后通过 IVF/卵胞浆内单精子注射(ICSI)受孕的早期流产患者的早期流产组织中非整倍体率,以比较两组的非整倍体率。为了比较囊胚的非整倍体率,还分析了 404 例采用 GnRH-ant 方案或 GnRH-a 长方案的胚胎植入前遗传学检测-非整倍体(PGT-A)周期。
与 GnRH-a 长方案组相比,接受 IVF/ICSI 受孕的早期流产患者中,GnRH-ant 方案组的早期流产组织中非整倍体率显著更高(48.51% vs. 64.19%)。关于 PGT-A 周期,GnRH-ant 方案组囊胚非整倍体率显著高于 GnRH-a 长方案组(39.69% vs. 52.27%)。经分层和多元线性回归分析,GnRH-ant 方案与早期流产组织和囊胚中非整倍体风险增加显著相关[比值比(OR)(95%可信区间)1.81(1.21,2.71),OR(95%可信区间)1.65(1.13,2.42)]。此外,GnRH-ant 方案组的囊胚非整倍体率显著升高,但仅在年轻和正常卵巢反应者中升高[比值比(OR)(95%可信区间)5.07(1.99,12.92)]。
与 GnRH-a 长方案相比,GnRH-ant 方案与早期流产组织和囊胚中非整倍体率升高相关。这些结果应在多中心、随机对照试验中得到证实。